AR074545A1 - Proceso de preparacion de dihidroetorfina - Google Patents

Proceso de preparacion de dihidroetorfina

Info

Publication number
AR074545A1
AR074545A1 ARP090104700A ARP090104700A AR074545A1 AR 074545 A1 AR074545 A1 AR 074545A1 AR P090104700 A ARP090104700 A AR P090104700A AR P090104700 A ARP090104700 A AR P090104700A AR 074545 A1 AR074545 A1 AR 074545A1
Authority
AR
Argentina
Prior art keywords
dihydroetorfine
preparation process
compound
formula
preparation
Prior art date
Application number
ARP090104700A
Other languages
English (en)
Spanish (es)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074545(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0822342A external-priority patent/GB0822342D0/en
Priority claimed from GB0920699A external-priority patent/GB0920699D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR074545A1 publication Critical patent/AR074545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP090104700A 2008-12-08 2009-12-04 Proceso de preparacion de dihidroetorfina AR074545A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0822342A GB0822342D0 (en) 2008-12-08 2008-12-08 Dihydroetorphine
GB0920699A GB0920699D0 (en) 2009-11-26 2009-11-26 Dihydroetorphine

Publications (1)

Publication Number Publication Date
AR074545A1 true AR074545A1 (es) 2011-01-26

Family

ID=42046251

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104700A AR074545A1 (es) 2008-12-08 2009-12-04 Proceso de preparacion de dihidroetorfina

Country Status (31)

Country Link
US (4) US20120010231A1 (enExample)
EP (2) EP3018133A1 (enExample)
JP (2) JP5787764B2 (enExample)
KR (2) KR101992272B1 (enExample)
CN (2) CN104119349B (enExample)
AR (1) AR074545A1 (enExample)
AU (1) AU2009326196B2 (enExample)
CA (1) CA2745537C (enExample)
CL (1) CL2011001363A1 (enExample)
CY (1) CY1116875T1 (enExample)
DK (1) DK2370443T3 (enExample)
EA (1) EA022210B1 (enExample)
ES (1) ES2548881T3 (enExample)
HR (1) HRP20151138T1 (enExample)
HU (1) HUE025913T2 (enExample)
IL (1) IL213207B (enExample)
ME (1) ME02262B (enExample)
MX (2) MX2011006095A (enExample)
MY (1) MY159913A (enExample)
NZ (1) NZ593102A (enExample)
PA (1) PA8852801A1 (enExample)
PL (1) PL2370443T3 (enExample)
PT (1) PT2370443E (enExample)
RS (1) RS54309B1 (enExample)
SG (1) SG171456A1 (enExample)
SI (1) SI2370443T1 (enExample)
SM (1) SMT201500273B (enExample)
TW (2) TWI630208B (enExample)
UY (1) UY32295A (enExample)
WO (1) WO2010067101A1 (enExample)
ZA (1) ZA201104161B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
CA2896919C (en) 2012-12-31 2019-01-29 Rhodes Technologies Process for preparing 7.beta.-substituted 6.alpha.,14.alpha.-ethenomorphinans and 7.beta.-substituted 6.alpha.,14.alpha.-ethanomorphinans
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP3023427A1 (en) * 2014-11-19 2016-05-25 Siegfried AG Improved method of manufacturing buprenorphine and analogues thereof from oripavine
EP3067357A1 (en) * 2015-03-11 2016-09-14 Siegfried AG Method of manufacturing stereoisomers of buprenorphine and analogues thereof
GB201513441D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal delivery system
GB201513442D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal patch
CN114105875B (zh) * 2021-12-06 2023-11-03 四川大学 一种吗啡衍生物二氢埃托啡的合成方法
EP4613751A1 (en) 2024-03-07 2025-09-10 Siegfried AG Method of making chemical compounds useful for the synthesis of buprenorphine

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937214A (en) 1961-06-02 1963-09-18 J F Macfarlan & Company Ltd Oripavine derivatives
GB925723A (en) 1960-09-05 1963-05-08 J F Macfarlan & Company Ltd Novel thebaine derivatives
JPS59184182A (ja) 1983-04-02 1984-10-19 Res Inst For Prod Dev ３−ベンゾイルチオ−４、５α−エポキシ−７α−〔１（Ｒ）−ヒドロキシ−１−メチルベンチル〕−６−メトキシ−１７−メチル−６、１４−エンド−エタノモルヒナン
JPS62153214A (ja) 1985-12-26 1987-07-08 Nitto Electric Ind Co Ltd 医薬製剤
JPS62281815A (ja) 1986-05-27 1987-12-07 Teisan Seiyaku Kk 貼付剤及びその製造法
JPS63201119A (ja) 1987-02-17 1988-08-19 Kao Corp 貼付剤組成物
US4891377A (en) 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
PT95069B (pt) 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
WO1994006426A1 (en) 1992-09-21 1994-03-31 Qin Bo Yi Methods for identifying and using low/non-addictive opioid analgesics
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
AU703593B2 (en) 1995-06-07 1999-03-25 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
KR100204659B1 (ko) * 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
JPH10231248A (ja) 1997-02-19 1998-09-02 T T S Gijutsu Kenkyusho:Kk ジヒドロエトルフィン含有経皮吸収型製剤
ME00850B (me) 1998-08-27 2008-08-07 Pfizer Health Ab Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
CN101305994A (zh) 2000-04-26 2008-11-19 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
EP1272035A1 (en) 2000-07-13 2003-01-08 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
JP2005500373A (ja) 2001-08-10 2005-01-06 ポリチップ ファーマスーティカルズ プロプライエタリイ リミテッド モルヒネ様オピオイド化合物の誘導体
CN1233645C (zh) * 2001-09-14 2005-12-28 中国人民解放军军事医学科学院毒物药物研究所 新的东罂粟碱衍生物及其医药用途
AU2003219680A1 (en) 2002-01-23 2003-09-02 The Regents Of The University Of California Methods and compositions for reducing the development of drug tolerance and/or physical dependence
US20060177381A1 (en) 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1894563B2 (de) 2002-05-28 2022-04-27 ratiopharm GmbH Pflaster, enthaltend Fentanylum
CN100525767C (zh) 2002-06-10 2009-08-12 欧洲凯尔特公司 防止所含活性剂被误用的经皮给药器的处置系统
ATE423560T1 (de) 2002-08-20 2009-03-15 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
AU2002951965A0 (en) 2002-10-09 2002-10-24 Monash University Amidine compounds
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US20040208917A1 (en) 2003-04-16 2004-10-21 Wilfried Fischer Transdermal systems for the release of clonidine
EP1641441B1 (en) 2003-04-30 2014-03-12 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US20050113365A1 (en) 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
CN100500151C (zh) 2004-04-02 2009-06-17 北京万全阳光医药科技有限公司 一种水溶性药物舌下给药制剂
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
CA2604887A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US8574604B2 (en) 2005-04-15 2013-11-05 Interface Biologics, Inc. Methods and compositions for the delivery of biologically active agents
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
EP1928881A2 (en) 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
WO2007052308A2 (en) 2005-11-03 2007-05-10 Brain N' Beyond Biotech Pvt. Ltd. Glyco-phosphorylated biologically active agents
GB0523031D0 (en) 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2007065303A1 (en) 2005-12-09 2007-06-14 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Transdermal patch containing isosorbide dinitrate and bisoprolol
JP2009530307A (ja) 2006-03-15 2009-08-27 アルザ コーポレイション 骨減少症を予防し、または治療するための副甲状腺ホルモン薬の経皮送達のための装置、並びに方法
USD576282S1 (en) 2006-06-16 2008-09-02 Activatek, Inc. Adhesive transdermal medicament patch
USD625017S1 (en) 2006-08-11 2010-10-05 Hisamitsu Pharmaceutical Co., Inc. Medical transdermal patch
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
CN100512817C (zh) 2006-11-15 2009-07-15 闫章年 复方噻拉嗪注射液及制备工艺
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
JP2010514789A (ja) 2006-12-27 2010-05-06 アベール ファーマシューティカルズ インコーポレイテッド 副腎皮質ステロイド投与のための経皮的方法及びパッチ
AU2008223328B2 (en) * 2007-03-06 2012-10-11 SpecGx LLC Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
KR100929560B1 (ko) 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2298277A1 (en) 2009-09-09 2011-03-23 Labtec GmbH Transdermal patch formulation
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Also Published As

Publication number Publication date
AU2009326196B2 (en) 2016-08-11
UY32295A (es) 2010-06-30
IL213207A0 (en) 2011-07-31
JP5787764B2 (ja) 2015-09-30
TWI541246B (zh) 2016-07-11
CY1116875T1 (el) 2017-04-05
US9206190B2 (en) 2015-12-08
ZA201104161B (en) 2016-05-25
US9481681B2 (en) 2016-11-01
IL213207B (en) 2018-01-31
ES2548881T3 (es) 2015-10-21
US20150133483A1 (en) 2015-05-14
PL2370443T3 (pl) 2016-01-29
HRP20151138T1 (hr) 2015-11-20
TWI630208B (zh) 2018-07-21
PT2370443E (pt) 2015-10-23
HK1161720A1 (en) 2012-08-03
DK2370443T3 (en) 2015-11-09
PA8852801A1 (es) 2010-04-21
CN102307877B (zh) 2015-12-16
US20170267687A1 (en) 2017-09-21
HUE025913T2 (en) 2016-04-28
EA022210B1 (ru) 2015-11-30
KR20110098801A (ko) 2011-09-01
CN104119349A (zh) 2014-10-29
US20160115174A1 (en) 2016-04-28
US10745406B2 (en) 2020-08-18
CN102307877A (zh) 2012-01-04
TW201022274A (en) 2010-06-16
KR101992272B1 (ko) 2019-06-24
TW201531476A (zh) 2015-08-16
AU2009326196A2 (en) 2012-08-30
JP6151307B2 (ja) 2017-06-21
CN104119349B (zh) 2017-04-12
EP2370443B1 (en) 2015-08-05
JP2012510985A (ja) 2012-05-17
MY159913A (en) 2017-02-15
SI2370443T1 (sl) 2015-12-31
KR20170082665A (ko) 2017-07-14
RS54309B1 (sr) 2016-02-29
SG171456A1 (en) 2011-07-28
EP2370443A1 (en) 2011-10-05
ME02262B (me) 2016-02-29
EA201170781A1 (ru) 2012-01-30
CA2745537C (en) 2017-01-17
JP2015157864A (ja) 2015-09-03
MX2011006095A (es) 2011-09-22
CL2011001363A1 (es) 2011-09-23
NZ593102A (en) 2013-10-25
US20120010231A1 (en) 2012-01-12
CA2745537A1 (en) 2010-06-17
EP3018133A1 (en) 2016-05-11
MX359363B (es) 2018-09-26
WO2010067101A1 (en) 2010-06-17
AU2009326196A1 (en) 2011-06-23
SMT201500273B (it) 2016-01-08

Similar Documents

Publication Publication Date Title
AR074545A1 (es) Proceso de preparacion de dihidroetorfina
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
CY1112722T1 (el) Μυκητοκτονες συνθεσεις
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
UA109547C2 (uk) Композиція для боротьби з захворюванням рослин і спосіб боротьби з захворюванням рослин
SMAP201100019A (it) Composti organici.
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
CR20110432A (es) Pirimidinas fusionadas
AR068403A1 (es) Proceso e intermediarios para la preparacion de inhibidores de integrasa
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
BR112015015368A2 (pt) composições de absorventes de dejetos de animais revestidas debaixa densidade
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
SV2011003902A (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5- hidroxitriptamina-6
AR095097A1 (es) Compuestos de fenoxietoxi
MY149154A (en) Novel microbiocides
AR114133A2 (es) Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
DOP2010000250A (es) Procedimiento de preparacion de combretastatina
EA200971019A1 (ru) Способы получения (r)-2-метилпирролидина и (s)-2-метилпирролидина и их солей винной кислоты
EA201690467A1 (ru) Промышленный способ синтеза улипристала ацетата и его 4'-ацетильного аналога
BR112012008952A2 (pt) microbicidas
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
BR112013024314A2 (pt) derivados quinolina como fungicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure